n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 17th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

Enumeral Biomedical Holdings, Inc. (ENUM)

Today we are reporting on Enumeral Biomedical Holdings, Inc. (ENUM), here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is discovering and developing novel antibody immunotherapies, which assist the immune system in attacking diseased cells. The Company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of its technology via strategic collaborations. Its unique platform enables it to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases. Enumeral Biomedical Holdings is based in Cambridge, Massachusetts and the Company lists on the OTC Bulletin Board.

Enumeral Biomedical is enabling and quickening the discovery and development of novel antibody immunotherapies, or immunomodulators that are validated with its human-driven immune profiling platform. Its immunoprofiling platform harnesses The Power of Human™. Enumeral believes that its cellular functional profiling techniques provide for a deeper understanding of the diversity of human responses and provide a more rational foundation to guide immunotherapy design and development. The Company believes it has a unique ability to widely interrogate the human immune microenvironment for candidate selection and validation.

Enumeral believes its unique capabilities enable it to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. The core technology underlying its platform was developed at, and licensed from, the Massachusetts Institute of Technology, Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral Biomedical is building a pipeline centered on next-generation checkpoint modulators, with initial targets including PD-1, TIM3, LAG-3, TIGIT, and VISTA. In developing these agents, its researchers apply a proprietary immune profiling technology platform, which measures functioning of the human immune system at the level of individual cells. This provides important insights for candidate selection and validation. Enumeral aims to move its lead PD-1 antagonist into clinical testing during the second half of 2016, with additional programs moving toward IND-enabling studies.

Recently, Enumeral Biomedical announced that it entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center. Scientists from Enumeral Biomedical and MD Anderson will collaborate on the discovery and development of novel monoclonal antibodies against specified targets in immuno-oncology, taking advantage of Enumeral’s antibody discovery and patient-centric immune profiling platform and MD Anderson’s preclinical and development expertise and infrastructure. With this agreement, Enumeral Biomedical and MD Anderson will share the costs of such research and development (R&D) activities, Additionally, each will be granted the right to receive a percentage of the net income from product sales or any payments associated with licensing or otherwise partnering a program with a third party.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Wednesday's trading session at $0.18, up 8.43%, on 53,600 volume with 6 trades. The average volume for the last 60 days is 60,448 and the stock's 52-week low/high is $0.1652/$0.98.

Andrea Electronics Corp. (ANDR)

Stock Guru reported previously on Andrea Electronics Corp. (ANDR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Andrea Electronics Corp. designs, develops, and manufactures audio technologies and equipment for enhancing applications needing high performance quality voice input. Mr. Frank A.D. Andrea Sr. originally established Andrea Radio Corp. in 1934 and was a leader in radio production in the 1940’s. Andrea Radio was known for the “Cadillac of televisions” in the 1950’s. The Company flew into space providing the astronaut audio system for the Mercury spacecraft in the early 1960’s. Andrea Electronics’ shares trade on the OTCQB.

The Bohemia, New York Company is an innovator of digital audio input enhancement software, computer headsets, and array microphone technologies. Additionally, it is an industry leading developer of product solutions that optimize the performance of voice user interfaces for different applications.

Andrea Electronics’ microphone array and other advanced noise cancellation technologies have been embedded into hundreds of millions of computers and other devices. The Company’s patented Digital Super Directional Array (DSDA™), patented PureAudio™, and patented EchoStop™ far-field microphone technologies enhance a wide spectrum of audio products to eliminate background noise and ensure the optimum performance of voice applications.

Andrea Electronics’ products include Array Microphones, Active Noise Cancellation Microphone Headsets, USB Headsets, Headphones, Computer Microphones, USB Audio Adapters, Noise Reduction Software, and Echo Cancellation Software, which improves the performance and provides ease of use for applications. These applications include Speech Recognition, Voice over the Internet (VoIP), Video conferencing, Game chat, and live digital audio recordings. Among the more recent innovations from Andrea Electronics are SuperBeam Stereo Array Microphone headsets and the DA-250 digital microphone stand alone solution for original equipment manufacturers (OEMs).

The Company announced in April 2015 that it sold its headset product line to a group of private investors that will operate as Andrea Communications LLC. The sale of this product line will allow Andrea Electronics to focus on the ongoing development of its patented digital array microphones and noise reduction software for use with new mobile device chip platforms (ARM processors) and operating systems, including Linux and Android.

In November 2015, Andrea Electronics announced that it is delivering its DA-250, a digital noise canceling and digital signal processing circuit board, to Norcon Communications for integration into their Talk-Thru communicator Unit (TTU).

The TTU provides hands-free communication between individuals separated by security or isolation barriers. TTU is the most extensively used barrier intercom system of its kind in the world.

Andrea Electronics Corp. (ANDR), closed Wednesday's trading session at $0.0545, down 3.54%, on 13,890 volume with 4 trades. The average volume for the last 60 days is 35,089 and the stock's 52-week low/high is $0.0401/$0.086.

Emisphere Technologies, Inc. (EMIS)

PennyStockRumors.net, AddictivePennyStocks, PennyStocks24, FeedBlitz, OTCPicks, and SmallCapVoice reported previously on Emisphere Technologies, Inc. (EMIS), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Emisphere Technologies, Inc. is a specialty pharmaceutical company headquartered in Roseland, New Jersey. It has been transformed from a delivery systems development enterprise into a broader commercial-stage entity. The Company is centering on its initial commercial product, oral Eligen® B12. Further to Eligen®B12, Emisphere uses its proprietary Eligen® Technology to create new oral formulations of therapeutic agents. Emisphere Technologies lists on the OTC Bulletin Board.

The Company’s pipeline includes product candidates that have reached clinical development and an array of preclinical research and development programs. Emisphere is carrying out these programs in collaboration with pharmaceutical and biotechnology companies, and also independently.

Its Oral Eligen® B12 meets substantial unmet patient and medical needs through combining B12 with its proprietary delivery system technology. Through building on the oral Eligen® B12 product, Emisphere’s intention is to establish a sound product portfolio platform on which to expand its B12 therapeutic franchise and expand internal new product development with new therapeutic agents.

In addition, Emisphere will continue to develop its existing drug delivery carrier partnerships and increase its carrier business through seeking and engaging in new global licensing opportunities. The Company’s strategy is to reemphasize the commercialization of Eligen® Oral B12, build new high-value partnerships, evaluate new commercial opportunities, and promote new uses for the Eligen® Technology.

The Company has developed an oral formulation of Eligen® B12 (1000 mcg) for use by B12 deficient individuals. It is covered by patent protection in the U.S. through roughly 2029. Novo Nordisk is utilizing Emisphere's Eligen® Technology to develop oral formulations of Novo Nordisk's insulin and GLP-1 receptor agonists.

Emisphere Technologies announced in March of 2015 the U.S. commercial availability of Eligen B12™. This product is the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the necessity for an injection.

Emisphere Technologies announced this past October an agreement with Novo Nordisk A/S (NVO) to develop and market oral formulations of four classes of Novo Nordisk’s investigational molecules targeting metabolic disorders including diabetes and obesity through using Emisphere Technologies’ oral Eligen Technology.

Emisphere Technologies, Inc. (EMIS), closed Wednesday's trading session at $0.50, down 3.85%, on 40,020 volume with 31 trades. The average volume for the last 60 days is 45,627 and the stock's 52-week low/high is $0.35/$0.90.

Pressure BioSciences, Inc. (PBIO)

SECFilings.com News, SmallCapFinancialWire, Marketbeat.com, Stock News Now, SmallCapVoice, HotStockProfits, Equity Observer, Value Penny Stocks, and Jet-Life Penny Stocks reported earlier on Pressure BioSciences, Inc. (PBIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pressure BioSciences, Inc. focuses on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (PCT).  PCT is a patented, enabling technology platform with numerous applications in the life sciences sample preparation market. PCT utilizes cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. OTCQB-listed, Pressure BioSciences is based in South Easton, Massachusetts.

The Company is concentrating its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications. Its primary application development and sales efforts are in the biomarker discovery and forensics areas.

The PCT Sample Preparation System (PCT SPS) allows for the safe, quick, and reproducible extraction of DNA, RNA, small molecules, and proteins from a wide assortment of cells and tissues, particularly those considered ‘hard-to-lyse’. The PCT SPS employs a Barocycler NEP3220, in concert with PULSE™ Tubes.

Pressure BioSciences’ products include Barocycler Instruments, Shredders, PULSE Tubes (PT), PCT MicroTubes and PCT MicroCaps, PCT µPestle System, The Barozyme™ HT48, and also Kits & Reagents. Additionally, Pressure BioSciences is an authorized distributor of Constant Systems Ltd. products in the United States, Mexico, and Canada.

The Barozyme HT48 is a first-in-class, high throughput, PCT-based instrument. It can process up to 48 samples simultaneously using Pressure BioSciences’ proprietary BaroFlex 8-well, single-use processing strips. Jointly, the new Barozyme HT48 instrument and BaroFlex 8-well processing strips make up the Barozyme HT48 High-throughput System (the Barozyme HT48 System).

Last month, SCIEX, a worldwide leader in life science analytical technologies, announced an exclusive co-marketing agreement with Pressure BioSciences. SCIEX said that the relationship will uniquely position it to address a significant challenge in complex sample preparation through marketing a total solution to increase the depth, breadth, and reproducibility of protein extraction, digestion and quantitation in all tissue kinds, such as challenging samples like tumors.

With the Agreement, Pressure BioSciences and SCIEX will promote pressure cycling technology (PCT) sample preparation systems such as PCT-HD (PCT High Definition) with SWATH® Acquisition based next-generation proteomics, TripleTOF® Systems, QTRAP® Systems, and Triple Quad Systems. This emphasis on improved sample preparation, a vital step performed in research laboratories around the world, will enable scientists to extract more proteins reproducibly from complex sample types, possibly yielding superior biological insights and discoveries.

Pressure BioSciences, Inc. (PBIO), closed Wednesday's trading session at $0.33, up 6.45%, on 35,300 volume with 12 trades. The average volume for the last 60 days is 70,539 and the stock's 52-week low/high is $0.20/$0.49.

Endurance Exploration Group, Inc. (EXPL)

Today we are reporting on Endurance Exploration Group, Inc. (EXPL), here at the QualityStocks Daily Newsletter.

Endurance Exploration Group, Inc., via its subsidiary, Endurance Exploration Group, LLC, concentrates on archaeologically sensitive exploration and recovery of deep-ocean shipwrecks around the world. The Clearwater, Florida Company focuses on aquatic research, survey, inspection, and recovery projects, as well as maritime contract services and consulting services.  Since 2009, Endurance Exploration has collected historical data and deep-sea equipment. Endurance Exploration Group was formerly known as Tecton Corp. It changed its corporate name to Endurance Exploration Group, Inc. in January of 2014.

The Company’s mission is to seek and recover long-lost riches from ships vanished in the depths of the seas. It utilizes advanced technology, underwater robotics, and intensive historical research as an exploration enterprise. Moreover, its plan is to recover bullion precious metals, numismatic-grade coinage, non-ferrous metals, and other valuable cargos from historic and modern shipwrecks. Endurance Exploration Group has developed an initial "High Interest" list of around 400 shipwrecks.

Utilizing criteria including, but not limited to, depth, potential search area, legal concerns, difficulty of excavation and potential value, the Company further gleaned the "High Interest" list to roughly two-dozen targets, the "Target List".  For a shipwreck to qualify for its "Target List", and to possibly move ahead as an "Operational Target" (OT) - one that Endurance Exploration may consider for the search and survey operation phase - the shipwreck must have known cargo of value; known navigational data; legal salvage and clear path to title; and potential returns greater than risk-adjusted cost of search and recovery.

Endurance Exploration Group (on May 15, 2015) entered into a contract with Eclipse Group, Inc. This contract is for Eclipse to provide remotely operated vehicle (ROV) and other subsea equipment charter services, along with the personnel needed in connection with the operation and monitoring of the ROV in connection with Endurance Exploration's investigation, inspection, and salvage of a shipwreck, believed to be that of the S.S. Connaught, positioned off the coast of New England. Mr. Steven Saint Amour, who serves as a member of the Board of Directors of Endurance Exploration Group, is a principal shareholder and officer of Eclipse Group.

Two of Endurance Exploration’s Projects, code-named "Sailfish" and "Black Marlin", have now reached operational or pre-operational status. Endurance Exploration has successfully completed Phase 1 of “Project Sailfish”. It has identified the wreck believed to be the aforementioned “S.S. Connaught.” This is a mid-19th century steamship. It was reportedly lost with a cargo of gold coins. The S.S. Connaught sunk on its second voyage.

For project "Black Marlin”, the Company has secured a three-year contract with a sovereign island nation in the Indian Ocean. This contract is for the survey and recovery of a Colonial-era merchant vessel carrying silver. In addition, this contract allows for other potentially valuable "targets of opportunity" within the territorial waters of this nation.

Endurance Exploration Group, Inc. (EXPL), closed Wednesday's trading session at $0.325, up 58.54%, on 3,397 volume with 2 trades. The average volume for the last 60 days is 1,550 and the stock's 52-week low/high is $0.10/$1.00.

graphic

The QualityStocks
Company Corner

graphic
graphic

Oakridge Global Energy Solutions, Inc. (OGES)

The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.70, up 14.75%, on 20,551 volume with 25 trades. The stock’s average daily volume over the past 60 days is 18,634, and its 52-week low/high is $0.20/$2.40.

Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.

Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.

The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.

Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer

Oakridge Global Energy Solutions, Inc. Company Blog

Oakridge Global Energy Solutions, Inc. News:

Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016

Oakridge Providing Batteries for Unmanned Maritime Vessels

Oakridge Sells Interest in Leclanche S.A., Releasing Funding for Corporate Growth

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0449, up 6.90%, on 799,295 volume with 54 trades. The stock’s average daily volume over the past 60 days is 441,715, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma Announces Management Expansion and Business Updates

Nutra Pharma Corp.ís (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck

Nutra Pharma Letter to Shareholders

Agora Holdings, Inc. (AGHI)

The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.365, up 1.42%, on 725,773 volume with 264 trades. The stock’s average daily volume over the past 60 days is 118,680, and its 52-week low/high is $0.03/$2.50.

Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.

Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.

For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.

Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.

Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer

Agora Holdings, Inc. Company Blog

Agora Holdings, Inc. News:

Agora Holdings Inc.'s Geegle Media Set to Release FRAME This Month

Agora Holdings, Inc. (AGHI) CEO Featured in Exclusive QualityStocks Interview

Agora Holdings, Inc. (AGHI) Announces Engagement of QualityStocks Corporate Communications Suite

Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.095, up 1.06%, on 69,999 volume with 10 trades. The stock’s average daily volume over the past 60 days is 43,103, and its 52-week low/high is $0.0137/$0.34.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview

Giggles Ní Hugs Signs Agreement with New York-Based Chardan Capital Markets

Giggles N Hugs to present at the 8th annual LD Micro Conference main event

OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.90, up 1.12%, on 11,390 volume with 5 trades. The stock’s average daily volume over the past 60 days is 3,875, and its 52-week low/high is $0.45/$1.00.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

OurPet's (OPCO) Expects New Product Line to Make Big Splash at Global Pet Expo

OurPet's Commits to Further Innovation in Pet Products That Enhance Pet/Owner Relationship

Dean Tsengas Named Chief Operations Officer of OurPet's Company

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Wyatt Investment Research
(LINE)

2.

Daily Trade Alert
(LNCO)

3.

Investing Futures
(FOSL)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251